# Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease

> **NCT06431971** · PHASE2 · NOT_YET_RECRUITING · sponsor: **InnoMedica Schweiz AG** · enrollment: 40 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Talineuren
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06431971
- **Lead sponsor:** InnoMedica Schweiz AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08
- **Primary completion:** 2025-11
- **Final completion:** 2025-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06431971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06431971, "Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06431971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*